Isobavachalcone Attenuates MPTP-Induced Parkinson's Disease in Mice by Inhibition of Microglial Activation through NF-κB Pathway
Related Experiment Video
Updated: Mar 9, 2026
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Haoran Jing1,2, Shaoxia Wang2, Min Wang1
1Laboratory of Genome Engineering, The Beijing Institute of Basic Medical Sciences, Beijing, China.
Abstract:
Parkinson's disease (PD) is a complex multi-system and age-related neurodegenerative disorder. The intervention targeting neuroinflammation in PD patients is one effective strategy to slow down or inhibit disease progression. Microglia-mediated inflammatory response plays an important role in Parkinson's, Alzheimer's and other cerebral diseases. Isobavachalcone is a main component of Chinese herb medicine Psoralea corylifolia, which function includes immunoregulation, anti-oxidation and the regulation of β-amyloid (Aβ42) deposited in hippocampus in Alzheimer's patients. Whether it has the therapeutic effect on Parkinson's disease, however, is unclear. In this study, we found that isobavachalcone could effectively remit Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP), prolong the residence time of mice on Rota-rod and alleviate the neuronal necrosis. It also inhibited the over-activation of microglia, and decreased the expression of IL-6 and IL-1β in the brain of PD mice. In vitro, isobavachalcone could inhibit nuclear factor-kappaB (NF-κB) pathway through inhibiting the LPS-induced transfer of NF-κB subunit from cytoplasm to nucleus in BV-2 cells. Isobavachalcone decreased the LPS-induced oxidative stress and the expression of inflammatory cytokines, and provided a neuroprotective effect by antagonizing microglia-mediated inflammation. Our results indicated that isobavachalcone may be a candidated drug against Parkinson's disease with great clinical potential.
Insights
Isobavachalcone, derived from Psoralea corylifolia, shows therapeutic potential for Parkinson's disease (PD). It reduces neuroinflammation and neuronal damage by inhibiting microglial activation and the NF-κB pathway.
Area of Science:
- Neuroscience
- Pharmacology
- Immunology
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder where neuroinflammation, particularly microglia-mediated responses, plays a key role.
- Targeting neuroinflammation is a promising therapeutic strategy for PD.
- Isobavachalcone, from Psoralea corylifolia, has known immunoregulatory and anti-oxidative properties, but its effect on PD was unknown.
Purpose of the Study:
- To investigate the therapeutic potential of isobavachalcone in a Parkinson's disease model.
- To elucidate the mechanisms underlying isobavachalcone's effects on neuroinflammation and neuroprotection.
Main Methods:
- A mouse model of Parkinson's disease was induced using MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).
- Behavioral tests (Rota-rod) and histological analysis were performed to assess PD symptoms and neuronal damage.
- Microglial activation, inflammatory cytokine expression (IL-6, IL-1β), and the NF-κB pathway were analyzed in vivo and in vitro (BV-2 cells stimulated with LPS).
Main Results:
- Isobavachalcone treatment ameliorated PD symptoms in mice, improving motor function and reducing neuronal necrosis.
- It significantly inhibited microglial over-activation and decreased the expression of IL-6 and IL-1β in PD mouse brains.
- In vitro, isobavachalcone suppressed LPS-induced NF-κB pathway activation, oxidative stress, and inflammatory cytokine production in BV-2 cells, demonstrating neuroprotective effects.
Conclusions:
- Isobavachalcone exhibits significant therapeutic effects against MPTP-induced Parkinson's disease.
- Its mechanism involves antagonizing microglia-mediated inflammation by inhibiting the NF-κB pathway.
- Isobavachalcone represents a potential therapeutic candidate for Parkinson's disease with considerable clinical promise.
